Want to see GKOS full AI Analyst Report?
GKOS Stock Chart & Stats
$124.79
$1.50(0.96%)
At close: 4:00 PM EST
$124.79
$1.50(0.96%)
Day’s Range― - ―
52-Week Range$73.16 - $157.71
Previous CloseN/A
Volume137.72K
Average Volume (3M)981.54K
Market Cap
$8.95B
Enterprise Value$6.07K
Total Cash (Recent Filing)$276.69M
Total Debt (Recent Filing)$103.06M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Jul 29, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.28
Shares Outstanding58,733,910
10 Day Avg. Volume741,241
30 Day Avg. Volume981,541
Financial Highlights & Ratios
PEG Ratio-1.87
Price to Book (P/B)9.84
Price to Sales (P/S)12.73
P/FCF Ratio-119.57
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$162.55Price Target Upside30.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$630.40M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Upgraded GuidanceRecord Q1 sales and a raised full‑year sales target reflect durable commercial adoption, led by iDose TR. Strong top‑line momentum across U.S. and international glaucoma franchises signals expanding procedure volumes and product penetration that can sustain growth over the next several quarters.
High & Improving Gross MarginSustained high gross margins indicate favorable product mix and scalable manufacturing economics for implantable devices and consumables. Durable margin strength improves the odds that incremental revenue will flow to operating leverage as SG&A/R&D growth moderates, supporting eventual profitability.
Conservative Leverage / Strong Balance SheetLow leverage provides financial flexibility to fund near‑term commercial launches and R&D without heavy refinancing risk. A stronger balance sheet reduces liquidity pressure while the business scales, extending runway for execution and improving resilience against sector shocks.
Bears Say
Negative Operating & Free Cash FlowPersistent negative operating and free cash flow means the business remains reliant on external liquidity to fund growth and launches. Even with improved burn versus prior years, ongoing cash deficits constrain reinvestment flexibility and raise financing needs over the medium term.
Material UnprofitabilityDespite accelerating revenue and higher gross margins, wide operating and net losses persist as management increases opex to commercialize new products. Sustained negative margins risk equity dilution or constrained investment if profitability is not demonstrably trending toward break‑even.
Reimbursement & Channel Access HeadwindsDurable commercial uptake depends on payer policies and site‑of‑care transitions (buy‑and‑bill to specialty pharmacy). Lengthened claim adjudication, prior‑auth workflows and channel shifts can slow revenue recognition, depress near‑term volumes and complicate scaling across US and international markets.
Glaukos News
GKOS FAQ
What was Glaukos’s price range in the past 12 months?
Glaukos lowest stock price was $73.16 and its highest was $157.71 in the past 12 months.
What is Glaukos’s market cap?
Glaukos’s market cap is $8.95B.
When is Glaukos’s upcoming earnings report date?
Glaukos’s upcoming earnings report date is Jul 29, 2026 which is in 13 days.
How were Glaukos’s earnings last quarter?
Glaukos released its earnings results on Apr 29, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.281 by $0.101.
Is Glaukos overvalued?
According to Wall Street analysts Glaukos’s price is currently Undervalued.
Does Glaukos pay dividends?
Glaukos does not currently pay dividends.
What is Glaukos’s EPS estimate?
Glaukos’s EPS estimate is -0.22.
How many shares outstanding does Glaukos have?
Glaukos has 58,733,910 shares outstanding.
What happened to Glaukos’s price movement after its last earnings report?
Glaukos reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.281. Following the earnings report the stock price went up 22.837%.
Which hedge fund is a major shareholder of Glaukos?
Currently, no hedge funds are holding shares in GKOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Glaukos Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$162.55 (30.26% Upside)
$162.55 (30.26% Upside)
Blogger Sentiment
Neutral
GKOS Sentiment 50%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 319.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.31%
12-Months-Change
Fundamentals
Return on Equity
-26.46%
Trailing 12-Months
Asset Growth
-7.54%
Trailing 12-Months
Company Description
Glaukos
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
GKOS Stock 12 Month Forecast
Average Price Target
$162.55
▲(30.26% Upside)
Technical Analysis
Integer Holdings
―
Ufp Technologies
―
Tandem Diabetes Care
―
LivaNova
―
Irhythm Technologies
―
Ownership Overview
3.91% Insiders
37.91% Mutual Funds
0.27% Other Institutional Investors
33.49% Public Companies and
Individual Investors